12/18
07:07 am
tlsi
TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Low
Report
TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
12/17
03:27 pm
tlsi
TriSalus Life Sciences (NASDAQ:TLSI) had its price target raised by analysts at Canaccord Genuity Group Inc. from $11.00 to $12.00. They now have a "buy" rating on the stock.
Low
Report
TriSalus Life Sciences (NASDAQ:TLSI) had its price target raised by analysts at Canaccord Genuity Group Inc. from $11.00 to $12.00. They now have a "buy" rating on the stock.
12/15
06:03 pm
tlsi
TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript [Seeking Alpha]
Low
Report
TriSalus Life Sciences, Inc. (TLSI) Discusses Innovative Approaches for Thyroid Artery Embolization and Tumor-Targeted Therapies Transcript [Seeking Alpha]
12/4
04:12 pm
tlsi
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025 [Yahoo! Finance]
Medium
Report
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025 [Yahoo! Finance]
12/4
04:01 pm
tlsi
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
Medium
Report
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
12/2
03:46 pm
tlsi
TriSalus Life Sciences (NASDAQ:TLSI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
TriSalus Life Sciences (NASDAQ:TLSI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/29
12:31 am
tlsi
TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by analysts at
Wall St
Low
Report
TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by analysts at
Wall St
11/26
02:21 pm
tlsi
TriSalus Life Sciences (NASDAQ:TLSI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
TriSalus Life Sciences (NASDAQ:TLSI) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
08:00 am
tlsi
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™
Low
Report
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™
11/14
12:27 am
tlsi
TriSalus Life Sciences Inc (TLSI) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... [Yahoo! Finance]
Medium
Report
TriSalus Life Sciences Inc (TLSI) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... [Yahoo! Finance]
11/13
07:34 pm
tlsi
TriSalus Life Sciences, Inc. (TLSI) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
TriSalus Life Sciences, Inc. (TLSI) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
04:23 pm
tlsi
TriSalus Life Sciences, Inc. (TLSI) Discusses Pressure-Enabled Drug Delivery and Advances in Uterine Fibroid Embolization Transcript [Seeking Alpha]
Low
Report
TriSalus Life Sciences, Inc. (TLSI) Discusses Pressure-Enabled Drug Delivery and Advances in Uterine Fibroid Embolization Transcript [Seeking Alpha]
11/11
04:05 pm
tlsi
TriSalus Life Sciences to Participate in Upcoming Investor Conferences
Low
Report
TriSalus Life Sciences to Participate in Upcoming Investor Conferences
11/10
08:00 am
tlsi
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025
Medium
Report
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025
10/30
08:00 am
tlsi
TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call
Medium
Report
TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call
9/28
03:33 am
tlsi
TriSalus Life Sciences (NASDAQ:TLSI) was downgraded by analysts at
Wall
Low
Report
TriSalus Life Sciences (NASDAQ:TLSI) was downgraded by analysts at
Wall